Immunocore Holdings PLC
IMCR
查看详细走势图
31.980USD
+1.060+3.43%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.59B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.43%
5天
-1.75%
1月
-5.27%
6月
+0.16%
今年开始到现在
-7.87%
1年
+6.42%
查看详细走势图
TradingKey Immunocore Holdings PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
Immunocore Holdings PLC当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名28/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价67.94。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Immunocore Holdings PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Immunocore Holdings PLC亮点
亮点风险
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
业绩高增长
公司营业收入稳步增长，连续3年增长77.91%
估值合理
公司最新PE估值-54.78，处于3年历史合理位
机构减仓
最新机构持股50.63M股，环比减少15.97%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值2.42K
分析师目标
根据
17
位分析师
买入
评级
67.938
目标均价
+115.67%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Immunocore Holdings PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Immunocore Holdings PLC简介
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
公司代码IMCR
公司Immunocore Holdings PLC
CEOJallal (Bahija)
网址https://www.immunocore.com/
相关品种
